COVID-19 drug trial pulled before it even started
NCT ID NCT04356677
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study planned to test an inhaled medicine called Virazole (ribavirin) in adults hospitalized with COVID-19 who had serious breathing trouble. The goal was to see if the drug was safe and could improve oxygen levels. However, the trial was withdrawn before enrolling any volunteers, so no results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Virazole (ribavirin) given as an inhaled mist
What this could lead to
If it worked, this could point toward a treatment for severe COVID-19 breathing distress.
What could go wrong
The study was withdrawn before any participants were enrolled, so no results are available. Ribavirin has known side effects and may not be effective against COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.